Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have improved the field of cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular immune-related adverse events (irAEs) with high mortality and morbidity have been observed, including myocarditis, pericarditis, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousif, Laura I., Screever, Elles M., Versluis, Daniëlle, Aboumsallem, Joseph Pierre, Nierkens, Stefan, Manintveld, Olivier C., de Boer, Rudolf A., Meijers, Wouter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256640/
https://www.ncbi.nlm.nih.gov/pubmed/37079251
http://dx.doi.org/10.1007/s11912-023-01414-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256640/
https://www.ncbi.nlm.nih.gov/pubmed/37079251
http://dx.doi.org/10.1007/s11912-023-01414-4

Ejemplares similares